GlassScriptPhysician profile
Michael D Hargrove
NPI 1336114115
$22,715.52
in general payments reported to CMS, 2019-2025
22 companies · $1,898 in 2025
The $1,898 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,613 · 2020: $1,701 · 2021: $2,192 · 2022: $3,072 · 2023: $2,537 · 2024: $8,702 · 2025: $1,898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,530 · Consulting Fee: $4,535 · Travel and Lodging: $1,045 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,530.29 |
| Consulting Fee | $4,535.00 |
| Travel and Lodging | $1,044.57 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $6,201.14 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $3,239.77 | 2019-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $2,337.97 | 2021-2025 | |
| Axsome Therapeutics, INC. | $1,557.91 | 2022-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $1,502.32 | 2022-2023 | Quviviq |
| Allergan, INC. | $1,288.74 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $1,105.82 | 2019-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $941.59 | 2021-2025 | Caplyta |
| Lundbeck LLC | $917.90 | 2019-2025 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $791.27 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $601.55 | 2019-2022 | |
| Alkermes, INC. | $578.98 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $494.77 | 2019-2025 | |
| Corium, LLC | $385.24 | 2022-2023 | Azstarys |
| Adlon Therapeutics L.P. | $326.54 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $149.87 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $86.26 | 2022-2025 | Qelbree, Qelbree |
| Bausch Health US, LLC | $66.28 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $52.27 | 2021-2022 | |
| Eisai INC. | $46.38 | 2020-2022 | |
| Neuronetics, INC. | $23.38 | 2019 | |
| Ironshore Pharmaceuticals INC. | $19.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hargrove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.